Spectral AI

Spectral MD develops AI-powered technology that uses predictive analytics and algorithms to assist clinicians in making accurate and timely treatment decisions. The company's flagship product, DeepView, is an AI-driven burn wound imaging device designed for use in emergency departments, trauma centers, and burn centers. DeepView integrates proprietary imaging technology and AI-enabled algorithms to analyze burn wounds and distinguish between healthy and damaged tissue beneath the skin's surface. This technology provides clinicians with an objective and immediate assessment of a wound's healing potential, enabling them to determine whether a burn will heal on its own or require surgery.

In clinical studies, DeepView has demonstrated a burn diagnostic accuracy rate of 92% on the first day, significantly higher than the estimated 50% accuracy of non-specialists and 70% accuracy of burn specialist assessments. The DeepView system received Breakthrough Device Designation from the FDA in 2017 for its burn indication.

Spectral MD was established in 2009 through technology transfer from the University of Texas Southwestern. Initially focused on predicting pressure ulcers for bedridden patients, the company shifted its attention to developing DeepView as a surgical triage tool for burn victims in mass casualty events, securing contracts with the Biomedical Advanced Research and Development Authority (BARDA) from 2013 to 2021.

In September 2023, Spectral MD (now listed as Spectral AI on Nasdaq) secured a multi-year BARDA contract worth up to USD 149 million for the advanced development of DeepView. The initial award of nearly USD 55 million supports clinical validation and FDA clearance for commercial marketing and distribution, enabling the deployment of up to 30 DeepView devices at burn centers and emergency rooms.